Brady Walker, MD
Urology · Springfield, ORNPI 1346300530
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (49.8%), travel and lodging and education — rather than concentrated in one kind of arrangement. Urogpo LLC accounts for 75.9% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2019 at $2,472 and has fallen 94.7% since, to $131 in 2025.
Across 44 payments — averaging $63.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Urogpo LLC$2K
- Johnson & Johnson$295
- Sumitomo Pharma America, Inc.$60
- Tolmar, Inc.$60
- AbbVie$45
- Astellas Pharma US Inc$39
- plus $179 from 9 others
What the payments were for
- Travel & lodging$1,36148%
- Food & beverage$1,40250%
- Education$512%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Urogpo LLC | 3 | $2,137 |
| Johnson & Johnson(2 entities) | 22 | $295 |
| Sumitomo Pharma America, Inc. | 2 | $60 |
| Tolmar, Inc. | 2 | $60 |
| AbbVie(2 entities) | 3 | $45 |
| Astellas Pharma US Inc | 2 | $39 |
| AstraZeneca | 1 | $35 |
| Valencia Technologies Corporation | 1 | $28 |
| Bayer | 1 | $22 |
| Amgen | 1 | $22 |
| Novartis | 1 | $19 |
| Coloplast | 1 | $17 |
| Endo Pharmaceuticals Inc. | 1 | $14 |
| Sun Pharmaceutical Industries Inc. | 1 | $14 |
| Travere Therapeutics, Inc. | 2 | $8 |
How this compares
$2,814 in reported general payments places this provider in the 60th percentile of 153 urology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NubeqaDarolutamide | 43 | $568,036 |
| ErleadaApalutamide | 29 | $425,922 |
| XtandiEnzalutamide | 19 | $261,588 |
| YonsaAbiraterone Acet,submicronized | 12 | $124,903 |
| ZytigaAbiraterone Acetate | 12 | $118,177 |
| MyrbetriqMirabegron | 106 | $84,311 |
| GemtesaVibegron | 39 | $21,225 |
| Tamsulosin Hcl | 611 | $10,938 |
| Testosterone | 45 | $8,560 |
| Solifenacin Succinate | 146 | $4,624 |
| Finasteride | 279 | $3,950 |
| Testosterone Cypionate | 68 | $3,144 |
| Methenamine Hippurate | 31 | $2,640 |
| Trimethoprim | 27 | $2,231 |
| Abiraterone Acetate | 15 | $1,972 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BayerNubeqa | $22 | $568,03643 claims |
| Johnson & JohnsonErleada, Zytiga | $295 | $544,09841 claims |
| Astellas Pharma US IncXtandi, Myrbetriq | $39 | $345,899125 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $60 | $21,22539 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 153 urology providers in Oregon.
Other urology in Springfield
- Bryan MehlhaffSpringfield$1M
- Kevin KrughoffSpringfield$54K
- David DimarcoSpringfield$7K
- Dawn BodellSpringfield$4K
- Brenton SherwoodSpringfield$3K
- Lance MarrPortland$323K
- Matt AshleyBend$212K
- da David JiangPortland$65K
- Kim ThaiMedford$57K
- Kyle GillisClackamas$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.